LACTOLOGY FOUNDATION

This ATC class (A04AB58) comprises fixed combinations containing promethazine, a first‑generation H1 antihistamine used as an antiemetic and antiallergic agent.medpedia.framar

ATC class A04AB58 overview

ATC A04AB58 belongs to the group “Antiemetics and antinauseants – antihistamines,” specifically combinations in which promethazine is a key active component. These medicinal products are intended to manage nausea and vomiting, often in the context of motion sickness, peri‑operative use, or associated allergic symptoms such as rhinitis and urticaria.medpedia.framar

Pharmacological profile

Promethazine is a phenothiazine derivative that acts primarily as a competitive antagonist at H1 histamine receptors, with additional anticholinergic and sedative properties due to central nervous system (CNS) depressant effects. Structurally, it differs from antipsychotic phenothiazines by the branching of its side chain and the lack of ring substitution, resulting in pronounced antihistaminic and antiemetic activity but minimal antipsychotic effect.medpedia.framar

In combinations (A04AB58), promethazine may be co‑formulated with agents such as other antiemetics, analgesics, or antispasmodics to broaden the clinical spectrum, for example improving control of vomiting while also addressing pain or gastrointestinal spasm. The overall pharmacodynamic profile of such combinations reflects additive or synergistic CNS depressant and anticholinergic burdens, which is relevant for toxicity and lactation safety assessment.medpedia.framar

Indications

Medicinal products in A04AB58 (promethazine, combinations) are used for:

• Allergic rhinitis and conjunctivitis when nausea or vomiting coexist or are anticipated (e.g. motion sickness, peri‑operative states).medpedia.framar
• Acute and chronic urticaria, medication and food allergies, and reactions to insect bites, especially when pruritus, nausea and vomiting require simultaneous control.medpedia.framar

Promethazine‑containing combinations are also employed as antiemetics for diverse causes of nausea and vomiting, including post‑operative, drug‑induced, and vestibular origin.medpedia.framar

Dosage and administration

The typical oral dosage of promethazine in such combinations, as represented in the Bulgarian monograph, is 25 mg once daily in tablet form for adults, although exact regimens depend on the specific co‑formulated substance and national product information. Preparations in this ATC class are prescription‑only medicines, requiring medical supervision due to CNS depressant and interaction risks.medpedia.framar

Contraindications and precautions

Use of promethazine combinations is contraindicated in patients with known hypersensitivity to promethazine or any component of the combination product. Extreme caution is warranted in individuals with pre‑existing respiratory depression, severe hepatic impairment, narrow‑angle glaucoma, prostatic hypertrophy, or cardiovascular disease because of the additive anticholinergic and hypotensive effects.medpedia.framar

Given the strong sedative properties, patients should be warned about impairment of psychomotor performance, with avoidance of driving and operation of machinery, especially when other CNS depressants are used concomitantly. Elderly patients and children are at particular risk of paradoxical CNS reactions and respiratory depression, making risk–benefit evaluation crucial in these populations.medpedia.framar

Adverse effects and toxicity

Common adverse reactions of promethazine combinations include pronounced drowsiness, somnolence, disorientation, weakness, and dry mouth, reflecting CNS depressant and anticholinergic actions. Cardiovascular effects such as hypotension or, less frequently, hypertension, tachycardia or bradycardia may occur, especially at higher doses or in susceptible patients.medpedia.framar

Neurological toxicity may manifest as tremor, convulsions, torticollis and agitation or hysteria, particularly in overdose or in paediatric use. Allergic and dermatologic reactions such as dermatitis, photosensitivity and urticaria are reported, along with hematological abnormalities including leukopenia and thrombocytopenia. Respiratory toxicity may present as asthma attacks, nasal obstruction and respiratory depression, a key concern in overdose or when combined with other depressants.medpedia.framar

Drug interactions

Promethazine‑containing combinations can potentiate and prolong the effects of other CNS depressants including alcohol, barbiturates, opioids, general anaesthetics and sedative analgesics, increasing the risk of profound sedation and respiratory depression. Concomitant use with epinephrine is discouraged, as promethazine may blunt or unpredictably modify the vasopressor response.medpedia.framar

Co‑administration with anticholinergic agents can amplify anticholinergic toxicity (tachycardia, urinary retention, ileus, delirium), while combinations with monoamine oxidase (MAO) inhibitors are contraindicated due to the risk of severe CNS and autonomic adverse reactions. These interaction profiles are central to toxicological evaluation and should be explicitly considered when counselling lactating patients who may already receive polypharmacy.medpedia.framar

Lactation safety considerations

Promethazine is expected to be excreted into breast milk in small amounts, as a lipophilic, low‑molecular‑weight drug; however, robust quantitative data for A04AB58 fixed combinations are limited. Based on its pharmacology, potential risks to the breastfed infant include sedation, irritability, poor feeding and, at higher maternal exposures or in vulnerable neonates, respiratory depression.medpedia.framar

Additional concerns arise from anticholinergic effects (possible negative impact on infant gut motility and urinary function) and theoretical reduction of maternal prolactin and milk production, particularly with repeated high doses or in early lactation. When promethazine combinations are clinically necessary in breastfeeding women, toxicological‑lactological risk assessment should prioritize: minimum effective dose and shortest duration, avoidance in preterm or medically fragile infants, and close monitoring for sedation, feeding difficulties and breathing irregularities.medpedia.framar

In many lactation‑focused guidelines, non‑sedating second‑generation antihistamines and non‑antihistaminic antiemetics are preferred alternatives; promethazine combinations are generally reserved for situations where safer agents are ineffective or contraindicated. Individual product characteristics, co‑active substances and national recommendations must be consulted before use during breastfeeding, and shared decision‑making with the mother is essential.medpedia.framar

Regulatory and clinical use notes

Medicinal products under ATC A04AB58 are prescription‑only and should be dispensed on the basis of medical assessment, with documentation of indication, duration and monitoring plan in breastfeeding patients. For toxicological‑lactological databases, A04AB58 can be classified as “sedating H1 antihistamine combinations with antiemetic use – use with caution in lactation, prefer alternatives; monitor infant closely if exposure is unavoidable.”medpedia.framar